Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Comparison of integrated PET/MRI with PET/CT in evaluation of endometrial cancer: a retrospective analysis of 81 cases.

Bian LH, Wang M, Gong J, Liu HH, Wang N, Wen N, Fan WS, Xu BX, Wang MY, Ye MX, Meng YG.

PeerJ. 2019 Jul 15;7:e7081. doi: 10.7717/peerj.7081. eCollection 2019.

2.

Establishment of the PDTX model of gynecological tumors.

Yang W, Fan WS, Ye MX, Li Z, Gu CL, Zhu YP, Hao YP, Wang ZQ, Wang L, Meng YG.

Am J Transl Res. 2019 Jun 15;11(6):3779-3789. eCollection 2019.

3.

Massive antibody discovery used to probe structure-function relationships of the essential outer membrane protein LptD.

Storek KM, Chan J, Vij R, Chiang N, Lin Z, Bevers J 3rd, Koth CM, Vernes JM, Meng YG, Yin J, Wallweber H, Dalmas O, Shriver S, Tam C, Schneider K, Seshasayee D, Nakamura G, Smith PA, Payandeh J, Koerber JT, Comps-Agrar L, Rutherford ST.

Elife. 2019 Jun 25;8. pii: e46258. doi: 10.7554/eLife.46258.

4.

Long noncoding RNA DARS-AS1 acts as an oncogene by targeting miR-532-3p in ovarian cancer.

Huang K, Fan WS, Fu XY, Li YL, Meng YG.

Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2353-2359. doi: 10.26355/eurrev_201903_17379.

5.

A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies.

Vij R, Lin Z, Chiang N, Vernes JM, Storek KM, Park S, Chan J, Meng YG, Comps-Agrar L, Luan P, Lee S, Schneider K, Bevers J 3rd, Zilberleyb I, Tam C, Koth CM, Xu M, Gill A, Auerbach MR, Smith PA, Rutherford ST, Nakamura G, Seshasayee D, Payandeh J, Koerber JT.

Sci Rep. 2018 May 8;8(1):7136. doi: 10.1038/s41598-018-25609-z.

6.

[Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].

Du XX, Yang H, Zhang HJ, Li LA, Fan WS, Meng YG.

Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):679-686. doi: 10.3760/cma.j.issn.0529-567X.2017.10.007. Chinese.

PMID:
29060966
7.

[Efficacy of gamma-irradiated adipose-derived stem cells for treatment of thin endometrium in rats].

Ye MX, Yu L, Wang SF, Fan WS, Meng YG.

Nan Fang Yi Ke Da Xue Xue Bao. 2017 May 20;37(5):575-580. Chinese.

PMID:
28539277
8.

[Clinical application of robotic plat form in the treatment of early ovarian cancer].

Ye MX, Yu L, Fan WS, Wang M, Bian LH, Gu CL, Zhao LY, Li LA, Meng YG.

Zhonghua Yi Xue Za Zhi. 2017 Apr 4;97(13):982-985. doi: 10.3760/cma.j.issn.0376-2491.2017.13.004. Chinese.

PMID:
28395414
9.

[Clinical analysis of 21 cases with short fetal femur in the third trimester].

Ren Y, You YQ, Zhou HH, Wang LX, Xu H, Li RB, Wang SJ, Xie XX, Meng YG, Lu YP.

Zhonghua Fu Chan Ke Za Zhi. 2017 Feb 25;52(2):86-92. doi: 10.3760/cma.j.issn.0529-567X.2017.02.004. Chinese.

PMID:
28253570
10.

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.

Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJ, Watts RJ, Couch JA, Meng YG, Atwal JK, Brezski RJ, Spiess C, Ernst JA.

J Biol Chem. 2017 Mar 3;292(9):3900-3908. doi: 10.1074/jbc.M116.767749. Epub 2017 Jan 11.

11.

Evading pre-existing anti-hinge antibody binding by hinge engineering.

Kim HS, Kim I, Zheng L, Vernes JM, Meng YG, Spiess C.

MAbs. 2016 Nov/Dec;8(8):1536-1547. Epub 2016 Aug 9.

12.

miR-139-5p regulates proliferation, apoptosis, and cell cycle of uterine leiomyoma cells by targeting TPD52.

Chen H, Xu H, Meng YG, Zhang Y, Chen JY, Wei XN.

Onco Targets Ther. 2016 Oct 11;9:6151-6160. eCollection 2016.

13.

Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.

Gong Q, Hazen M, Marshall B, Crowell SR, Ou Q, Wong AW, Phung W, Vernes JM, Meng YG, Tejada M, Andersen D, Kelley RF.

MAbs. 2016 Aug-Sep;8(6):1098-106. doi: 10.1080/19420862.2016.1189049. Epub 2016 May 24.

14.

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.

Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, Ross J, Wyatt SK, Gandham VD, Carano RA, Dunshee DR, Wu AL, Haley B, Anderson K, Warming S, Rairdan XY, Lewin-Koh N, Zhang Y, Gutierrez J, Baruch A, Gelzleichter TR, Stevens D, Rajan S, Bainbridge TW, Vernes JM, Meng YG, Ziai J, Soriano RH, Brauer MJ, Chen Y, Stawicki S, Kim HS, Comps-Agrar L, Luis E, Spiess C, Wu Y, Ernst JA, McGuinness OP, Peterson AS, Sonoda J.

EBioMedicine. 2015 May 30;2(7):730-43. doi: 10.1016/j.ebiom.2015.05.028. eCollection 2015 Jul.

15.

Quantitation of Circulating Neuropilin-1 in Human, Monkey, Mouse, and Rat Sera by ELISA.

Lu Y, Meng YG.

Methods Mol Biol. 2015;1332:39-48. doi: 10.1007/978-1-4939-2917-7_3.

PMID:
26285744
16.

Detection and Quantification of VEGF Isoforms by ELISA.

Vernes JM, Meng YG.

Methods Mol Biol. 2015;1332:25-37. doi: 10.1007/978-1-4939-2917-7_2.

PMID:
26285743
17.

Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics.

Gadkar K, Pastuskovas CV, Le Couter JE, Elliott JM, Zhang J, Lee CV, Sanowar S, Fuh G, Kim HS, Lombana TN, Spiess C, Nakamura M, Hass P, Shatz W, Meng YG, Scheer JM.

Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5390-400. doi: 10.1167/iovs.15-17108.

PMID:
26275136
18.

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.

Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang J, Meng YG, Eigenbrot C, Pantua H, Diao J, Kapadia SB, Deng R, Kelley RF.

MAbs. 2014;6(5):1255-64. doi: 10.4161/mabs.29809. Epub 2014 Oct 30.

19.

p16 expression in patients with cervical cancer and its prognostic significance: meta-analysis of published literature.

Huang K, Li LA, Meng YG, Fu XY.

Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:64-9. doi: 10.1016/j.ejogrb.2014.10.016. Epub 2014 Oct 24.

PMID:
25461355
20.

Real-time immuno-polymerase chain reaction in a 384-well format: detection of vascular endothelial growth factor and epidermal growth factor-like domain 7.

Zhang J, Vernes JM, Ni J, Nelson C, Wong A, Chen ST, Asundi A, Vandlen R, Meng YG.

Anal Biochem. 2014 Oct 15;463:61-6. doi: 10.1016/j.ab.2014.06.024. Epub 2014 Jul 8.

PMID:
25013989
21.

Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling.

Huang K, Li LA, Meng YG, You YQ, Fu XY, Song L.

Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):507-11. doi: 10.1111/bcpt.12270. Epub 2014 Jun 17.

22.

A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Auerbach MR, Yan D, Vij R, Hongo JA, Nakamura G, Vernes JM, Meng YG, Lein S, Chan P, Ross J, Carano R, Deng R, Lewin-Koh N, Xu M, Feierbach B.

PLoS Pathog. 2014 Apr 10;10(4):e1004060. doi: 10.1371/journal.ppat.1004060. eCollection 2014 Apr.

23.

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.

Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S.

MAbs. 2013 Nov-Dec;5(6):896-903. doi: 10.4161/mabs.26436.

24.

ARHI overexpression induces epithelial ovarian cancer cell apoptosis and excessive autophagy.

Li J, Cui G, Sun L, Wang SJ, Tian S, Guan Z, Fan WS, Yan ZF, Yang YZ, You YQ, Fu XY, Li LA, Huang K, Li YL, Meng YG.

Int J Gynecol Cancer. 2014 Mar;24(3):437-43. doi: 10.1097/IGC.0000000000000065.

PMID:
24476894
25.

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.

Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N.

Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4.

26.

STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer.

Li J, Cui G, Sun L, Wang SJ, Li YL, Meng YG, Guan Z, Fan WS, Li LA, Yang YZ, You YQ, Fu XY, Yan ZF, Huang K.

Oncol Rep. 2013 Jul;30(1):165-70. doi: 10.3892/or.2013.2414. Epub 2013 Apr 22.

PMID:
23604529
27.

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR, Ferrara N.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6079-84. doi: 10.1073/pnas.1303302110. Epub 2013 Mar 25.

28.

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.

Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS.

Clin Cancer Res. 2013 Feb 15;19(4):929-37. doi: 10.1158/1078-0432.CCR-12-2535. Epub 2012 Nov 20.

29.

Real-time quantification of antibody-short interfering RNA conjugate in serum by antigen capture reverse transcription-polymerase chain reaction.

Tan M, Vernes JM, Chan J, Cuellar TL, Asundi A, Nelson C, Yip V, Shen B, Vandlen R, Siebel C, Meng YG.

Anal Biochem. 2012 Nov 15;430(2):171-8. doi: 10.1016/j.ab.2012.08.018. Epub 2012 Aug 26. Review.

PMID:
22929697
30.

Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.

Xue R, Jin ZL, Chen HX, Yuan L, He XH, Zhang YP, Meng YG, Xu JP, Zheng JQ, Zhong BH, Li YF, Zhang YZ.

Eur Neuropsychopharmacol. 2013 Jul;23(7):728-41. doi: 10.1016/j.euroneuro.2012.06.001. Epub 2012 Jun 28.

PMID:
22748419
31.

Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.

Kelley RF, Meng YG.

Methods Mol Biol. 2012;901:277-93. doi: 10.1007/978-1-61779-931-0_18.

PMID:
22723108
32.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

33.

Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma.

Hu J, Zhu LR, Liang ZQ, Meng YG, Guo HY, Qu PP, Ma CL, Xu CJ, Yuan BB.

J Zhejiang Univ Sci B. 2011 Oct;12(10):787-95. doi: 10.1631/jzus.B1100166.

34.

The development of peptide-based tools for the analysis of angiogenesis.

Fedorova A, Zobel K, Gill HS, Ogasawara A, Flores JE, Tinianow JN, Vanderbilt AN, Wu P, Meng YG, Williams SP, Wiesmann C, Murray J, Marik J, Deshayes K.

Chem Biol. 2011 Jul 29;18(7):839-45. doi: 10.1016/j.chembiol.2011.05.011.

35.

TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma.

Lin K, Taylor JR Jr, Wu TD, Gutierrez J, Elliott JM, Vernes JM, Koeppen H, Phillips HS, de Sauvage FJ, Meng YG.

PLoS One. 2011 Apr 29;6(4):e18608. doi: 10.1371/journal.pone.0018608.

36.

Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.

Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.

J Immunol Methods. 2011 Feb 28;365(1-2):132-41. doi: 10.1016/j.jim.2010.12.014. Epub 2010 Dec 23.

PMID:
21185301
37.

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.

Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJ, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55. doi: 10.1073/pnas.1015855107. Epub 2010 Nov 16.

38.

[Design, synthesis and antidepressive activity of duloxetine derivatives].

Zhang YP, Xue R, He XH, Meng YG, Zhang YZ, Zhong BH.

Yao Xue Xue Bao. 2010 Jul;45(7):869-73. Chinese.

PMID:
20931784
39.

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR, Wong T, Chen Y, Ultsch M, Luis E, Ramani SR, Jackman J, Gonzalez L, Dennis MS, Chuntharapai A, DeForge L, Meng YG, Xu M, Eigenbrot C, Lee WP, Refino CJ, Balazs M, Wu LC.

J Clin Invest. 2010 Jun;120(6):2218-29. doi: 10.1172/JCI40141. Epub 2010 May 10.

40.

A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.

Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, Ferrara N, Lowman HB.

Cancer Res. 2010 Apr 15;70(8):3269-77. doi: 10.1158/0008-5472.CAN-09-4580. Epub 2010 Mar 30.

41.

Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration.

Lu Y, Xiang H, Liu P, Tong RR, Watts RJ, Koch AW, Sandoval WN, Damico LA, Wong WL, Meng YG.

MAbs. 2009 Jul-Aug;1(4):364-9. Epub 2009 Jul 29.

42.

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.

Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N.

Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7. doi: 10.1073/pnas.0902280106. Epub 2009 Apr 3.

43.

Characterization and regulation of bv8 in human blood cells.

Zhong C, Qu X, Tan M, Meng YG, Ferrara N.

Clin Cancer Res. 2009 Apr 15;15(8):2675-84. doi: 10.1158/1078-0432.CCR-08-1954. Epub 2009 Mar 31.

44.

The single-macro domain protein LRP16 is an essential cofactor of androgen receptor.

Yang J, Zhao YL, Wu ZQ, Si YL, Meng YG, Fu XB, Mu YM, Han WD.

Endocr Relat Cancer. 2009 Mar;16(1):139-53. doi: 10.1677/ERC-08-0150. Epub 2008 Nov 20.

PMID:
19022849
45.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W.

Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20.

PMID:
18641636
46.

A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors.

Gutierrez J, Konecny GE, Hong K, Burges A, Henry TD, Lambiase PD, Lee Wong W, Meng YG.

Clin Chem. 2008 Mar;54(3):597-601. doi: 10.1373/clinchem.2007.096099.

47.

Bv8 regulates myeloid-cell-dependent tumour angiogenesis.

Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N.

Nature. 2007 Dec 6;450(7171):825-31.

PMID:
18064003
48.

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation.

Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, Bullens SL, Seeber S, Fuentes ME, Labrijn AF, Graus YM, Miller LA, Schelegle ES, Hyde DM, Wu LC, Hymowitz SG, Martin F.

J Clin Invest. 2007 Dec;117(12):3868-78.

49.

Estrogenically regulated LRP16 interacts with estrogen receptor alpha and enhances the receptor's transcriptional activity.

Han WD, Zhao YL, Meng YG, Zang L, Wu ZQ, Li Q, Si YL, Huang K, Ba JM, Morinaga H, Nomura M, Mu YM.

Endocr Relat Cancer. 2007 Sep;14(3):741-53.

PMID:
17914104
50.

Supplemental Content

Support Center